Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings-Reference-Cited by-同舟云学术

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings

Published:2012-06-29 Issue:1 Volume:15 Page:3-14
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Holst J. J.¹,Vilsbøll T.²

Affiliation:

1. The Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Panum Institute; University of Copenhagen; Copenhagen; Denmark

2. Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital; University of Copenhagen; Copenhagen; Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01628.x/fullpdf

Reference103 articles.

1. http://www.who.int/mediacentre/factsheets/fs312/en/

2. Type 2 diabetes in the young: the evolving epidemic;Bloomgarden;Diabetes Care,2004

3. Addressing barriers to initiation of insulin in patients with type 2 diabetes;Peyrot;Prim Care Diabetes,2010

4. Clinical inertia in patients with T2DM requiring insulin in family practice;Harris;Can Fam Physician,2010

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures;Food Bioengineering;2024-09-04

2. Pharmacologic treatment of NAFLD/NASH and their related comorbidities;Metabolic Steatotic Liver Disease;2024

3. The emergence of obesity in type 1 diabetes;International Journal of Obesity;2023-12-14

4. Real‐world study of the concomitant use of biphasic insulin as part 30/70 with GLP‐1 receptor agonist versus first‐generation basal insulin with GLP‐1 receptor agonist in type 2 diabetes;Diabetic Medicine;2023-12-13

5. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes;BMC Endocrine Disorders;2023-02-01